deCODE genetics Earnings Conference Call (Q2 2009)  Today's Calls

Visit the TF Network Sites· Corporate IR Center · Institutional Investor Center · Individual Investor Center Download Plug-In Real Player 8 Basic Windows Media Player Other Conference Calls Other Aug 11 Calls Today's Calls

Call Details deCODE genetics Earnings Conference Call (Q2 2009) Tue, Aug 11, 2009, 8:00 am Eastern Listen to the archived event audio About deCODE genetics (NasdaqGM:DCGN) deCODE genetics, Inc., a bio-pharmaceutical company, develops and markets products for the treatment, diagnosis, and prevention of common diseases. It offers DNA-based diagnostic tests to detect single-letter variations in the human genome (SNPs), such as deCODE T2, which detects SNPs associated with risk of type 2 diabetes; and deCODE AF, which detects SNPs associated with risk of atrial fibrillation and stroke. The company also provides deCODE MI, which detects SNPs associated with early-onset heart attack/myocardial infarction; deCODE ProstateCancer, which detects SNPs linked to prostate cancer; deCODE Glaucoma, which detects SNPs linked to risk of exfoliation glaucoma; and deCODE BreastCancer, which detects SNPs linked to risk of various forms of breast cancer. In addition, its lead drug development programs include DG041 for the prevention of arterial thrombosis, which has completed additional clinical pharmacology studies; DG051 for the prevention of heart attack has completed Phase IIa clinical studies; DG031 for the prevention of heart attack has completed reformulation; and an investigational new drug application was filed for DG071 for Alzheimer's and other cognitive disorders. Further, the company’s DNA-based risk diagnostic tests in development include melanoma, basal cell cancer, bladder cancer, and lung cancer. Furthermore, it provides contract genotyping services; deCODEme, a consumer genetic analysis service; deCODEme Cardio for cardiovascular-related diseases; and deCODEme Cancer for several common types of cancer. The company serves pharmaceutical companies, biotechnology firms, pharmacogenomics companies, government institutions, research consortia, academic institutions, universities, and other research institutions in the United States and Europe. It has a strategic alliance with Illumina, Inc. to develop and commercialize molecular diagnostic products. deCODE genetics, Inc. was founded in 1996 and is headquartered in Reykjavik, Iceland. More Info: Quote | Chart | News | Profile | Reports | Research | SEC | Msgs | Insider | Financials